Skip to main content
PharmAbcine Inc. logo

PharmAbcine Inc. — Investor Relations & Filings

Ticker · 208340 ISIN · KR7208340000 KO Manufacturing
Open in API
Filings indexed 461 across all filing types
Latest filing 2024-01-11 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 208340

About PharmAbcine Inc.

http://pharmabcine.com/

PharmAbcine Inc. is a clinical-stage biotechnology company specializing in the development of fully human therapeutic monoclonal antibodies (mAbs). The company focuses on creating innovative treatments for diseases with high unmet medical needs, primarily in oncology, neovascular eye diseases, and other inflammatory and vascular disorders. Utilizing its proprietary human antibody library and discovery technologies, PharmAbcine advances a pipeline of next-generation IgG-based therapeutics. The company's mission is to contribute to human health by providing novel antibody-based drugs to patients.

Recent filings

Filing Released Lang Actions
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) from Pharmabcine regarding a decision on a capital increase (유상증자결정). It details the issuance of new shares, the third-party allocation, changes in the maximum shareholder, and the schedule for listing. This falls under the category of share issuance and capital changes.
2024-01-11 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the acquisition of shares by Tire Bank Co., Ltd. and its special related parties in PharmAbcine Inc., including the purpose of holding (management influence), the number of shares, and the source of funds. This corresponds to the 'Major Shareholding Notification' category.
2024-01-03 Korean
[기재정정]신주인수권부사채(해외신주인수권부사채포함)발행후만기전사채취득(제2회차)
Capital/Financing Update Classification · 100% confidence The document is a regulatory filing from the Korean Exchange (KRX) regarding the acquisition of bonds before maturity (specifically, Bond with Warrant - BW). It details the redemption of debt, the reason for the acquisition (put option exercise), and the subsequent cancellation of the bonds. This falls under capital structure changes and financing updates. While it is a correction filing, the core content relates to the company's capital/financing activities.
2023-12-28 Korean
신주인수권부사채(해외신주인수권부사채포함)발행후만기전사채취득
Capital/Financing Update Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) regarding the 'acquisition of bonds before maturity' (specifically Bond with Warrant, BW). It details the specific terms of the bond, the amount acquired, the reason (put option exercise), and the method of acquisition. This falls under capital structure changes and financing updates related to debt instruments. Given the specific nature of the filing regarding the company's own debt securities, it is best classified as a Capital/Financing Update.
2023-12-27 Korean
불성실공시법인지정예고(공시번복)
Regulatory Filings Classification · 100% confidence The document is a formal notice from a regulatory body (KOSDAQ) regarding the designation of a company as an 'unfaithful disclosure corporation' due to a disclosure reversal (cancellation of a third-party capital increase). This is a regulatory announcement concerning compliance and potential penalties, which fits the 'Regulatory Filings' (RNS) category as it does not fall into specific categories like legal proceedings or financial reports.
2023-12-27 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a decision for a third-party paid-in capital increase (유상증자결정) by PharmAbcine. It details the issuance of new shares, the purpose of the capital raise, the list of third-party allottees, and the impact on the company's shareholding structure. This type of filing is a formal announcement of a capital change/share issuance, which falls under the 'Share Issue/Capital Change' category.
2023-12-26 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.